NurExone Logo Rebrand-large.png
NurExone’s Regenerative Medicine Therapies To Be Recognized at Fall Conferences in the USA
23 oct. 2024 02h56 HE | NurExone Biologic Inc
NurExone’s Groundbreaking Exosome Therapies to be Showcased at Fall U.S. Conferences
NurExone Logo Rebrand-large.png
NurExone Biologic Announces Private Placement of up to $2M and Closes First Tranche for $1.61M
26 sept. 2024 16h03 HE | NurExone Biologic Inc
NurExone Biologic Announces Private Placement of up to $2M and Closes First Tranche for $1.61M
NurExone Logo Rebrand-large.png
NurExone Biologic Extends Global Reach with Presentations at Industry-Leading Conferences
12 sept. 2024 16h04 HE | NurExone Biologic Inc
NurExone Biologic Enhances Visibility in Pharmaceutical Industry with Technological Presentations at Major Global Events
Homing Post Injury - ExoPTEN
NurExone Demonstrates Extended Therapeutic Window of ExoPTEN Post Spinal-Cord Injury in Preclinical Study
06 sept. 2024 16h03 HE | NurExone Biologic Inc
NurExone demonstrates a longer timeframe of ExoPTEN treatment can be effectively administered post Spinal-Cord Injury
NurExone Logo Rebrand-large.png
NurExone Reports Second Quarter 2024 Financial Results and Provides Corporate Update
28 août 2024 08h34 HE | NurExone Biologic Inc
NurExone Reports Second Quarter 2024 Financial Results and Provides Corporate Update
NurExone Logo Rebrand-large.png
NurExone Biologic Invited to Present Groundbreaking ExoPTEN Therapy at Prestigious September Conferences
23 août 2024 16h03 HE | NurExone Biologic Inc
NurExone Biologic to present its innovative ExoPTEN therapy at key September conferences in Boston and New York, showcasing its leadership in regenerative
2024_Process Robustness
NurExone Biologic Achieves Key Milestone in Support of Robust Exosome Manufacturing Process
15 août 2024 16h03 HE | NurExone Biologic Inc
NurExone’s reliable production from diverse biological sources allows NurExone to optimize exosome production with consistency and efficiency
Figure 1
NurExone's ExoPTEN, loaded with siRNA, Demonstrates Ability to Target Injury and Inflammation Sites – New Study
09 août 2024 16h04 HE | NurExone Biologic Inc
NurExone announces promising new data for its ExoPTEN nanodrug, highlighting progress towards commercial-grade manufacturing
Figure 1
NurExone Announces the Transfer of Manufacturing of the Active Element in ExoPTEN Drug to a Commercial GMP Manufacturer
01 août 2024 16h04 HE | NurExone Biologic Inc
NurExone Announces the Transfer of Manufacturing of the Active Element in ExoPTEN Drug to a Commercial GMP Manufacturer
NurExone Logo Rebrand-large.png
NurExone Announces Further Expansion of ExoPTEN Patent Coverage
29 juil. 2024 16h04 HE | NurExone Biologic Inc
NurExone Announces Further Expansion of ExoPTEN Patent Coverage in Israel